Arcturus Therapeutics Holdings Inc. Insider Trading

ARCT

⊜ Compare

Last 12 months

No open-market buying or selling by insiders.

The last open-market buy by an executive or director was in Aug 2025.

Net open-market

0 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

0 / 0

executives and directors

Last open-market buy

Aug 2025

Aug 15, 2025

Get an email when ARCT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 15, 2025	Andy Sassine Chief Financial Officer	Bought	1,238	$16.56	21K	0.6%	Form 4

Aug 15, 2025
Andy Sassine
Chief Financial Officer · bought 1,238 at $16.56
21K
0.6% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ARCT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ARCT

CompareIntrinsic value

TNXPTonix Pharmaceuticals Holding Corp

$5.11-1.54%40

VRCAVerrica Pharmaceuticals Inc.

$3.46+5.02%40

VSTMVerastem Inc.

$9.85+0.82%40

JAGXJaguar Health, Inc.

$0.50-10.61%40

STOKStoke Therapeutics Inc.

$27.45+1.70%25

CPIXCumberland Pharmaceuticals Inc.

$4.44+3.02%13

BGMBGM Group Ltd.

$8.81-7.65%26

JANXJanux Therapeutics Inc.

$18.18+2.02%40

Held by ETFs

ARCT is in 14 US ETFs. The largest of them, with ARCT's weight in each:

Spot a number that looks wrong? Check it in ARCT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ARCT

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.